Hosny Ehab A, Al-Marzouki Zohair M H, Metwally Mohammed E S, Souaida Mamdouh Y S, Alshaik Abdel Rhman A M
College of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Boll Chim Farm. 2003 Oct;142(8):361-6.
Two formulations of insulin suppositories were prepared to contain different amounts of sodium salicylate and sodium cholate as absorption promoters and also of insulin with the purpose of obtaining the most effective formulation in reducing plasma glucose levels after rectal administration to diabetic patients. The results show that insulin suppositories containing 100 mg sodium salicylate and 100 or 200 U of crystalline insulin showed no significant difference in AUC, Cmax and Tmax and both formulations showed significant reduction in plasma glucose level compared to initial values within 1.5-2 h. The results from experiments carried out in health volunteers showed that 100 mg sodium salicylate is the optimum amount to be included in insulin suppositories producing significantly higher Cmax and AUC compared to those produced after rectal administration of insulin suppositories containing 50 or 200 mg sodium salicylate. The results also show that using sodium cholate in 50 mg amount did not produce any significant reduction in plasma glucose levels of insulin dependent diabetic patients given suppositories containing 100 U of insulin, but this amount in suppositories containing 200 U of insulin was able to produce significant (p < 0.05) reduction in plasma glucose level within 1 h which lasted till end of experiment producing Cmax of 29.7 +/- 6.61% at Tmax of 1.5 +/- 0.61 h. On increasing the amount of sodium cholate to 100 mg in the suppositories, a marked (p < 0.01) reduction in plasma glucose level took place and the Cmax increased to 47.7 +/- 12.24% at Tmax of 1.5 +/- 0.63 h. This resulted in AUC of 86.7 +/- 22.4 mg%h which was non significantly higher from that produced after administration of suppositories containing 50 mg sodium cholate and 200 U insulin (62.5 +/- 17.6 mg%h). The results also show that insulin suppositories containing 100 mg sodium cholate and 200 U insulin resulted in a non significant differences in Cmax and AUC from those produced by S.C. injection of insulin (20 U) but significantly (p < 0.001) shorter Tmax. This formulation also shows non significant differences in Tmax and AUC and significantly (p < 0.05) higher Cmax than from those produced after rectal administration of suppositories containing 100 mg of sodium salicylate and same amount of insulin. Further more this formulation produced severe hypoglycemia in control healthy volunteers within 1 h of administration producing Cmax of 57.0 +/- 18.8% at Tmax of 0.75 +/- 0.35 h. The results of this study showed that the formulation containing 100 mg of sodium cholate and 200 U of insulin tested in fasted insulin dependent diabetic patients produced a maximum % reduction in plasma glucose levels (Cmax) of 47.7 +/- 12.24% at tmax of 1.5 +/- 0.63 h compared to Cmax of 50.56 +/- 6.8% at tmax of 2.93 +/- 0.19 h resulted after subcutaneous injection of 20 U insulin. These suppositories produced an area under the curve (AUC) of 87 +/- 22.4 mg%h compared to an AUC of 81 +/- 13.4 mg%h obtained after subcutaneous injection. This formulation of suppositories studied in 7 insulin dependent diabetic patients was found to abolish the 2-h post-prandial significant rise in plasma glucose levels after meal. These results show that these insulin suppositories containing 100 mg of sodium cholate and 200 U of insulin can serve as effective buffer against meal related hyperglycemia. The suppositories were safe, effective, accepted and well tolerated by the tested individuals.
制备了两种胰岛素栓剂配方,其中含有不同量的水杨酸钠和胆酸钠作为吸收促进剂,还含有胰岛素,目的是获得在给糖尿病患者直肠给药后降低血糖水平最有效的配方。结果表明,含有100mg水杨酸钠和100或200U结晶胰岛素的胰岛素栓剂在AUC、Cmax和Tmax方面无显著差异,与初始值相比,两种配方在1.5 - 2小时内血糖水平均显著降低。在健康志愿者中进行的实验结果表明,100mg水杨酸钠是胰岛素栓剂中所含的最佳量,与含有50或200mg水杨酸钠的胰岛素栓剂直肠给药后相比,其产生的Cmax和AUC显著更高。结果还表明,对于接受含有100U胰岛素栓剂的胰岛素依赖型糖尿病患者,使用50mg胆酸钠并未使血糖水平有任何显著降低,但在含有200U胰岛素的栓剂中,该量能够在1小时内使血糖水平显著(p < 0.05)降低,直至实验结束,在Tmax为1.5 ± 0.61小时时Cmax为29.7 ± 6.61%。在栓剂中将胆酸钠的量增加到100mg时,血糖水平发生显著(p < 0.01)降低,在Tmax为1.5 ± 0.63小时时Cmax增加到47.7 ± 12.24%。这导致AUC为86.7 ± 22.4mg%h,与含有50mg胆酸钠和200U胰岛素的栓剂给药后产生的AUC(62.5 ± 17.6mg%h)相比无显著更高。结果还表明,含有100mg胆酸钠和200U胰岛素的胰岛素栓剂在Cmax和AUC方面与皮下注射胰岛素(20U)产生的结果无显著差异,但Tmax显著(p < <0.001)更短。该配方在Tmax和AUC方面也无显著差异,且与含有100mg水杨酸钠和相同量胰岛素的栓剂直肠给药后相比,Cmax显著(p < 0.05)更高。此外,该配方在给药后1小时内使对照健康志愿者出现严重低血糖,在Tmax为0.75 ± 0.35小时时Cmax为57.0 ± 18.8%。该研究结果表明,在空腹胰岛素依赖型糖尿病患者中测试的含有100mg胆酸钠和200U胰岛素的配方,与皮下注射20U胰岛素后在tmax为2.93 ± 0.19小时时产生的Cmax为50.56 ± 6.8%相比,在tmax为1.5 ± 0.63小时时血糖水平最大降低百分比(Cmax)为47.7 ± 12.24%。这些栓剂产生的曲线下面积(AUC)为87 ± 22.4mg%h,相比皮下注射后获得的AUC为81 ± 13.4mg%h。在7名胰岛素依赖型糖尿病患者中研究的这种栓剂配方被发现消除了餐后2小时血糖水平的显著餐后升高。这些结果表明,这些含有100mg胆酸钠和200U胰岛素的胰岛素栓剂可作为对抗与进餐相关的高血糖的有效缓冲剂。这些栓剂对受试个体是安全、有效、可接受且耐受性良好的。